Go Pro
NASDAQ:FBLG

FibroBiologics Q4 2025 Earnings Report

FibroBiologics logo
$0.92 +0.06 (+6.47%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$0.90 -0.02 (-2.26%)
As of 07/10/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

FibroBiologics EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.09
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Tuesday, February 24, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

FibroBiologics' Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

FibroBiologics Earnings Headlines

FibroBiologics (NASDAQ:FBLG) Shares Up 5.4% - Still a Buy?
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
FibroBiologics Secures New Private Placement Financing
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG), Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile